Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Monte Rosa Therapeutics Inc (NQ: GLUE ) 8.840 -0.060 (-0.67%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 4,563,355 Open 8.910 Bid (Size) 8.640 (1) Ask (Size) 8.890 (1) Prev. Close 8.900 Today's Range 8.485 - 9.120 52wk Range 2.911 - 12.40 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis October 28, 2024 The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases. Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's Intraday Session October 28, 2024 Via Benzinga Performance YTD +54.82% +54.82% 1 Month +73.67% +73.67% 3 Month +136.36% +136.36% 6 Month +53.47% +53.47% 1 Year +166.27% +166.27% More News Read More PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday October 28, 2024 Via Benzinga “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” October 28, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence Why Is Monte Rosa Therapeutics Stock Surging On Monday? October 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session October 28, 2024 Via Benzinga Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders October 28, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors October 23, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences August 28, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study August 19, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 Via InvestorPlace Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day July 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 June 27, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis June 14, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces Leadership Team Promotions May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease May 21, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 16, 2024 Via Benzinga Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering May 16, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session May 15, 2024 Via Benzinga Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants May 15, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer May 02, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
